Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease lynch syndrome
Phenotype C0476089|endometrial ca
Sentences 30
PubMedID- 25871621 Germline mlh1 mutations are frequently identified in lynch syndrome patients with colorectal and endometrial carcinoma demonstrating isolated loss of pms2 immunohistochemical expression.
PubMedID- 22940821 The prognosis of endometrial cancer in patients with lynch syndrome has not been established, the findings for colorectal cancer, however, suggest that the prognosis of lus cancer may be good for patients with lynch syndrome.
PubMedID- 24244552 Prevalence of lynch syndrome among patients with newly diagnosed endometrial cancers.
PubMedID- 23639481 Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with lynch syndrome.
PubMedID- 22306203 Prospective evaluation of molecular screening for lynch syndrome in patients with endometrial cancer
PubMedID- 25529831 Performance characteristics of a brief family history questionnaire to screen for lynch syndrome in women with newly diagnosed endometrial cancer.
PubMedID- 26197859 In summary, it is important to identify lynch syndrome among women with endometrial cancer for three reasons: (1) this will justify more frequent colorectal cancer surveillance, to avoid this cancer; (2) if diagnosed with colorectal cancer, there is an important therapeutic implication; and (3) their unaffected family members then have the opportunity to undergo genetic counseling and testing, and reduce their risks of colorectal and/or endometrial cancer(s).
PubMedID- 25562140 It is estimated that about 2%-5% of all diagnosed colorectal and endometrial cancers are due to lynch syndrome [1].
PubMedID- 24056992 Carried out a cost-effectiveness analysis comparing triage strategies for identifying endometrial cancer patients with lynch syndrome.30 they found that, relative to strategies of mmr gene sequence analysis for all women with endometrial cancer, for all diagnosed under age 60, or for all with endometrial cancer who meet amsterdam criteria, the osu strategy of ihc tumour analysis for all, followed by genetics referral and single-gene analysis except for those aged over 60 with loss of mlh1/pms2 and no concerning family history, had an incremental cost-effectiveness ratio (icer) of $13,812 per additional case detected, and would detect 858 of the estimated 920 incident lynch syndrome endometrial cancer patients annually.
PubMedID- 21537049 We estimated the costs and benefits of different testing criteria to identify lynch syndrome in women with endometrial cancer.
PubMedID- 26327831 Both ovarian and endometrial cancers are typical of lynch syndrome – a disease that results from a defect in dna mismatch repair genes (mmr), which leads to the microsatellite instability [13].
PubMedID- 23760948 Molecular pathogenesis of endometrial cancers in patients with lynch syndrome.
PubMedID- 22692286 Identifying lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas.
PubMedID- 26151267 Female hormonal factors and the risk of endometrial cancer in lynch syndrome.
PubMedID- 24933100 Objective: determine factors impacting the uptake of genetic counseling and results of genetic testing following universal tumor testing for lynch syndrome in patients with endometrial cancer.
PubMedID- 26219573 Screening for lynch syndrome among patients with newly diagnosed endometrial cancer: a comprehensive review.
PubMedID- 24096698 endometrial cancer is part of lynch syndrome, which is attributable to the inheritance of rare, highly penetrant mutations in dna mismatch repair genes (nicolaides et al.
PubMedID- 24396821 However, msi is also reported in as many as 90% to 95% of colorectal carcinomas and at least 75% of endometrial carcinomas associated with lynch syndrome [14].
PubMedID- 25371881 This is the first case report of an endometrial cancer patient with a lynch syndrome germline mutation without family history in korea.
PubMedID- 23842794 Chemoprevention of endometrial cancer in lynch syndrome: a step forward.
PubMedID- 23769810 The additional value of endometrial sampling in the early detection of endometrial cancer in women with lynch syndrome.
PubMedID- 20396392 This mutation rate is lower than that of lynch syndrome with endometrial cancer patients, of whom 15% show mmr mutations [62].
PubMedID- 23385444 Risks of colorectal and other cancers after endometrial cancer for women with lynch syndrome.
PubMedID- 26162329 Here, with the use of lynch syndrome in endometrial cancer as a model, some of the applications and intricacies of next-generation sequencing testing for hereditary cancer syndromes are reviewed.
PubMedID- 22187554 There is a higher incidence of nonendometrioid endometrial cancer in patients with lynch syndrome (43%) than in those with sporadic uterine tumors, despite younger mean age at diagnosis.
PubMedID- 25930067 The role of expanded testing for lynch syndrome in women with endometrial cancer.
PubMedID- 23225370 Application of research methods show improved identification and may facilitate appropriate referrals of endometrial cancer patients with possible lynch syndrome.
PubMedID- 24168969 Re: risks of colorectal and other cancers after endometrial cancer for women with lynch syndrome.
PubMedID- 23599155 Note, however, that pten immunohistochemistry is not useful in distinguishing endometrial carcinomas with lynch syndrome-associated loss of mmr from sporadic tumors with mlh1 loss secondary to mlh1 methylation.
PubMedID- 23888949 Utility of mlh1 methylation analysis in the clinical evaluation of lynch syndrome in women with endometrial cancer.

Page: 1